Study: Obesity and Alcohol is related to an increase in death in intestinal cancer among young people

Weight gain and alcohol consumption contribute to high mortality rates, due to intestinal cancer between people between the ages of 25 and 49 years in the European Union and the United Kingdom, although the death rates as a result of this type of cancer are generally reduced in Europe, according to a new study published by the ‘Annals of Oncology’, which predicts the death figure. that the greatest increase in the death rates of the disease among young people will see Britain as it will increase by 26% in men, and almost 39% in women in 2024, compared to 2018. Related health conditions, such as high blood sugar levels and diabetes. According to the research, there are additional reasons for excessive consumption of alcohol over time in the center, Northern Europe and Britain, and low physical activity. A large group of previous studies monitored a link between alcohol consumption and intestinal cancer. The countries where alcohol consumption, such as France and Italy, has not yet seen such noticeable increases in death rates. The intestinal cancer that affects young people tends to be more aggressive, with lower survival rates, compared to intestinal cancer diagnosed with the elderly. Researchers advise national governments to improve policies aimed at encouraging increased physical activity, reducing the number of people suffering from weight gain or obesity. In terms of prevention, researchers believe that governments should consider expanding the extent of intestinal cancer, to include younger ages, from the age of 45. Exam programs differ in Europe, but the increase in cases of intestinal cancer among young people in the United States has encouraged the work of preventative services to recommend the age at which the investigation begins for up to 45 years. The researchers have analyzed the death figures of cancer in the 27 countries in the European Union as a whole in Britain after collecting information about the death of the World Health Organization databases from 1970 to 2018 for most countries of the European Union and Britain. This is the 14th consecutive year in which researchers publish these expectations. The death of more than a million in respect of all types of cancer in the 27 countries in the European Union, researchers expect a decrease of 6.5% in death rates for all types of cancer from 132 per 100,000 population in 2018 to 123 per 100 thousand in 2024 for men, and 4% fall from 82.5 to 79 per 100 thousand among women. The study expected that nearly one million and 270 thousand and 800 people would die as a result of the disease in the European Union and in Britain, the study indicated that the death rate for all types of cancer in men would fall by 14% from 120 to 104 per 100 thousand, and by 10% from 92.5 to 83 per 100 thousand among women in 2024. pace in men Britain. The researchers expect mortality rates in 2024, which amounts to 28 men and 13.6 women per 100,000 in the European Union, and this represents a 15% decline in men since 2018, but there is no decline among women. In Britain, due to lung cancer, death rates will be 19 men and 16 women per 100,000, representing a decrease of 22% and 17% respectively among men and women. In both the European Union and Britain, intestinal cancer is now the second largest killer after lung cancer among men, and the third largest killer to breast and lung cancer in women, despite the low mortality rates, with the exception of British women. Compared to the year 2018, the total mortality rate due to intestinal cancer in the European Union is expected to drop by 5% to 15 men per 100 thousand in 2024, and by 9% to 8 women per 100 thousand. In Britain, it is expected to fall by 3% to 14 men per 100,000, but it will remain stable for women at about 10 per 100,000. The researchers say that the interpretation of these positive trends is due to improving the diagnosis and treatment of intestinal cancer. Mortality rates tend to decline in countries with a better possibility of performing early investigation and diagnosis, but the high mortality rate among young people is a concern. Mortality figures still improve in Europe and Britain due to breast cancer. In 2024, researchers expect a decrease of 6% of 14 per 100,000 women in the European Union in 2018, to 13 per 100,000 in 2024, and a decrease of 11% of 15 to 13 per 100,000 in Britain. The researchers believe that progress in the diagnosis of breast cancer contributes to this significant decrease in death rates, but improvements in the treatment and handling of the disease are still needed. The study indicates that pancreatic cancer, which is difficult to detect or successfully treated, is the only most important cancer, as it is not expected to have an improvement in the death rates of both sexes in the European Union. Pancreatic cancer represents more than 3% of the new cancer diagnoses in Europe, but accounts for about 7% of cancer deaths, which are the fourth main cause of death due to cancer. The death rates are expected to rise by 1.6% and 4% among men and women in the European Union respectively. But these trends are better in Britain, as they are expected to fall 7% among men and 2% among women. The causes of pancreatic cancer, according to the study, say the researchers that smoking is the most important risk factor for pancreatic cancer, but it only explains the increase in mortality rates over time, and it can also play weight gain, obesity, diabetes and excessive alcohol consumption. These expectations highlight the importance of combating and eventually eliminating tobacco use. Tobacco accounts for 25% of total cancer deaths between men and 15% among women in the European Union, and the most important risk factor of deaths caused by lung cancer and many other types of cancer, including pancreatic cancer. Expectations highlight the importance of bridging gaps between countries in Europe regarding the diagnosis and treatment of cancer. The death rates are still higher in Poland and other countries in Central and Eastern Europe, partly due to insufficient investigation programs to detect cancer, such as breast cancer, cervix, colon and rectum, as well as the inability to access the latest treatments.